• Journal of Chest Surgery
• /
• v.38 no.5 s.250
• /
• pp.366-370
• /
• 2005

Background: In general, cardiac surgery has been performed via median sternotomy. During the past decade, improvements in endoscopic equipment and operative techniques have resulted in development of minimally invasive cardiac operation using small incisions. With the advent of a voice controlled camera-holding robotic arm (AESOP 3000, Automated Endoscope System for Optimal Positioning), cardiac surgery entered the robotic age. Material and Method: Between April 2004 and December 2004, a total of seventy eight patients underwent robotic cardiac surgery, of whom sixty four patients underwent robot-assisted minimally invasive cardiac surgery via 5cm right lateral minithoracotomy using voice controlled robotic arm, femoral vessels cannulation, percutaneous internal jugular cannulation, transthoracic aortic cross clamp. Other fourteen patients underwent MIDCAB via internal mammary artery harvesting using AESOP. Result: Robotic cardiac surgery were mitral valve repair in 37 cases, mitral valve replacement in 10 cases, aortic valve replacement in 1 case, MIDCAB in 14 cases, ASD operation in 9 cases, and isolated Maze procedure in 1 case. In mitral operation, mean CPB time was $165.3\pm43.1$ minutes and mean ACC time was $110.4\pm48.2$ minutes. Median length of hospital stay was 6 days (range 3 to 30) in mitral operation, 4 days (range 2 to 7) in MIDCAB, and 4 days (range 2 to 6) in ASD operation. For complications, 3 patients were required by reoperation for bleeding. There was no hospital mortality. Conclusion: Our experience of robot cardiac surgery suggests that many cardiovascular surgeons will be able to perform minimally invasive cardiac operations through small incisions with robot-assisted video-direction. Well-designed studies and close long-term follow-up will be required to analyze the benefits of robot-assisted operation.

• Proceedings of the Korean Society of Medical Physics Conference
• /
• 2003.09a
• /
• pp.70-70
• /
• 2003

경피적관상동맥성형술(CPTCA)이나 스텐트삽입술 후에 발생하는 재협착을 방지하기 위한 방사선을 조사하는 방법 중에 베타 입자를 방출하는 액체 선원을 catheter풍선 내에 넣어 일정 시간 방사선 조사 시키는 방법이 있다. 조사시킬 혈관의 길이가 길어 한번의 방사선 조사가 어려울 경우 영역을 분할하여 두 번에 나누어 조사할 경우가 있다. 조사영역의 겹치는 부근의 흡수선량이 고선량이나 저선량이 되는가를 알기 위하여 두 풍선간의 접근 거리에 따른 혈관내벽의 흡수선량 분포를 알아보았다. 풍선내의 액체 선원은 Ho-l66을 이용하였고 Ho-l66의 물리적 반감기는 26.8시간이고 최대에너지 1.85 MeV, 평균에너지 0.69 MeV와 최대에너지 1.77 MeV, 평균에너지 0.65 MeV를 갖는 베타 입자를 방출한다. Ho-l66 의 방사선 흡수선량을 측정하기 위하여 GafChromic 필름(Nuclear Associates, Carle Place, NY, USA)을 이용하였고, 방사선이 조사된 필름의 optical density는 videodensitometer(Wellhofer, Schwarzen-bruck, Germany)를 이용하여 값을 읽었다. Catheter 풍선은 직경이 3 mm 이고 길이가 20 mm인 것을 이용하였다. 혈관 내벽의 최대 흡수선량을 표준화하여 겹치는 부분의 흡수선량 분포를 접근 거리에 따라 구하였다. 또한 몬테카를로 시abf레이션으로 확인하였다. 두 풍선의 겹치는 부근의 선량 분포는 풍선 중앙에서 중앙사이의 거리가 21 mm 일 때 중앙에서 20% 증가하였고, 거리가 22 mm일 때와 23 mm일 때 각각 10%와 40%의 감소를 보였다. 풍선 도자의 풍선 안에 베타입자 방출 액체 선원을 넣어 혈관내벽에 방사선 조사하는 방법은 비정거리가 짧아 혈관 내벽 부근에만 방사선을 조사시키고 그 외 중요 장기에는 영향을 덜 미치는 장점이 있다. 그러나 혈관 내벽 표면으로 부터의 거리에 따라 흡수선량이 급격히 떨어지는 분포를 이루기 때문에 두 개의 풍선이 겹치는 부근의 흡수선량은 아주 작은 접근 거리에서도 급격한 변화를 보였다. 따라서 시술 중에 겹치는 부분을 아주 적게 분할하여 정확하게 차례차례로 조사시키기 위해서는 신중한 거리 조정을 하여야 한다.

• Journal of Radiation Protection and Research
• /
• v.25 no.4
• /
• pp.191-195
• /
• 2000

This study was undertaken to estimate the exposed dose of the medical personnel during the intracoronary radiotherapy procedure as a part of ongoing SPARE (Seoul National University Hospital Post-Angioplasty Rhenium) trial. Data of thirty-four patients among forty-two irradiated patients participating in this trial due to coronary artery stenosis were retrospectively analyzed. Intracoronary radiotherapy was delivered to the patient immediately after angioplasty ballooning. Prescribed dose was 17 Gy to media of the diseased artery and was delivered with $^{188}Re$ filled balloon catheter. Dosimetry was carried out with GM counter at eight different points. Ten centimeter and forty centimeter from the patient's heart were selected to represent maximum and whole-body exposed dose of the operator, respectively. Median delivered dose was 111.6 mCi with average treatment time of 576 seconds. Average exposed dose rate at 10 cm and 40 cm from the patient's heart were 0.43 mSv/hr and 0.30 mSv/hr, respectively. Average exposed doses per treatment were 0.07 mSv and 0.05 mSv for 10 cm and 40 cm from the patient's heart, respectively. Exposed doses measured are much lower than recommended limit of 50 mSv for radiation workers or 1 mSv for general population in ICRP-60. This study proves that current method of intracoronary radiotherapy incorporated in this trial is very safe regarding radiation protection.